Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023 08:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
December 11, 2023 08:00 ET
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
December 08, 2023 09:10 ET
|
Spherix Global Insights
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021,...
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
December 07, 2023 12:01 ET
|
Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
Velocity Clinical Research expands to Poland
December 06, 2023 06:00 ET
|
Velocity Clinical Research, Inc.
Strong pipeline of Polish acquisition targets by end of 2023Hires ex-Parexel Global Head Site Solutions to lead Polish expansion LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research...
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China
December 04, 2023 08:28 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new...
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
December 04, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatmentData accepted for presentation at 47th Annual Macula...
Opthea to Present at the FLORetina 2023 Congress
December 01, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
GLOBAL ANNOUNCES AUTHORS FOR NEW EDITION OF 1ST EVIDENCE-BASED GLOBAL MEDICAL CARE GUIDELINES FOR ADULTS WITH DOWN SYNDROME
November 30, 2023 12:52 ET
|
Global Down Syndrome Foundation
Denver, CO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Today, Global Down Syndrome Foundation announced the roster of authors for the second edition of the first evidence-based GLOBAL Medical Care Guidelines...
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
November 30, 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...